Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Gabe Fernandez who wrote (190)	11/11/1998 7:36:00 PM
From: ADEL 7	Read Replies (2) \| Respond to of 1386

Gabe--- I also beg to disagree with you. First of all I have high respect for you and your knowledge. I can never forget your message on Oct. 7th . You analyzed the study and assured all investors that day. Back to our point. In my hospital there is only one neurosurgeon and more than 100 internists. We need our message to go to a big audience. This is the way I look at it. If it is published in Journal of Neurology only very few doctors will know about it. If we are looking for PR and we should because we have a solid company with excellent drug for TBI, then the study should be published for a large number of doctors. We need to communicate much better and to refine our message so that many investors become aware of our company. Lancet is a great journal but New England is considered an authoritative journal in USA as you well know. Best regard to you. Adel